AR030128A1 - Una preparacion solida altamente absorbible - Google Patents

Una preparacion solida altamente absorbible

Info

Publication number
AR030128A1
AR030128A1 ARP010103772A ARP010103772A AR030128A1 AR 030128 A1 AR030128 A1 AR 030128A1 AR P010103772 A ARP010103772 A AR P010103772A AR P010103772 A ARP010103772 A AR P010103772A AR 030128 A1 AR030128 A1 AR 030128A1
Authority
AR
Argentina
Prior art keywords
solid preparation
highly absorbable
absorbable solid
oral absorption
highly
Prior art date
Application number
ARP010103772A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of AR030128A1 publication Critical patent/AR030128A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Puede obtenerse una preparacion solida mejorada en cuanto a la absorcion oral y reducida en fluctuaciones de absorcion oral mediante la incorporacion de un ácido orgánico, en particular, ácido tartárico, en una preparacion solida que posee como ingrediente activo, un alto contenido de un compuesto de quinolona, en particular sitafloxacina, que posee poca solubilidad en agua a un pH casi neutro.
ARP010103772A 2000-08-08 2001-08-07 Una preparacion solida altamente absorbible AR030128A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000239233 2000-08-08

Publications (1)

Publication Number Publication Date
AR030128A1 true AR030128A1 (es) 2003-08-13

Family

ID=18730805

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103772A AR030128A1 (es) 2000-08-08 2001-08-07 Una preparacion solida altamente absorbible

Country Status (14)

Country Link
US (2) US6861071B2 (es)
EP (1) EP1308160A4 (es)
JP (1) JP3573287B2 (es)
KR (1) KR100878667B1 (es)
CN (1) CN1214792C (es)
AR (1) AR030128A1 (es)
AU (1) AU2001276748A1 (es)
BR (1) BR0113055A (es)
CA (1) CA2417764C (es)
MX (1) MXPA03001206A (es)
NO (1) NO323835B1 (es)
RU (1) RU2287328C2 (es)
TW (1) TWI278316B (es)
WO (1) WO2002011726A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828429B2 (en) * 2005-03-03 2014-09-09 Takeda Pharmaceutical Company Limited Release-control composition
CN113777180B (zh) * 2020-08-12 2023-05-02 济川药业集团有限公司 一种同时检测西他沙星及其多种异构体杂质的方法
CN113181125B (zh) * 2021-04-27 2022-07-19 海南通用三洋药业有限公司 一种西他沙星片剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
MY105136A (en) 1988-04-27 1994-08-30 Daiichi Seiyaku Co Optically active pyridonecarboxylic acid derivatives.
HU219594B (hu) * 1991-12-27 2001-05-28 Merck And Co. Inc. Szabályozott diszperziós hatóanyag-leadó eszköz és eljárás előállítására
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
EP0688772B1 (en) * 1994-06-16 1999-05-06 LG Chemical Limited Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation
DK0775702T3 (da) * 1994-08-12 2003-08-18 Toyama Chemical Co Ltd Hidtil ukendte quinolon- eller naphthylidoncarboxylsyrederivater eller salt deraf
US6057323A (en) * 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5847003A (en) * 1996-06-04 1998-12-08 Avon Products, Inc. Oxa acids and related compounds for treating skin conditions
US6709678B2 (en) * 1996-08-15 2004-03-23 Losan Pharma Gmbh Easy to swallow oral medicament composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
WO1998058928A1 (fr) * 1997-06-23 1998-12-30 Yoshitomi Pharmaceutical Industries, Ltd. Agent prophylactique ou therapeutique contre des maladies attribuables a une infection par des helicobacters
AUPO758297A0 (en) * 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
JP4299385B2 (ja) * 1997-07-15 2009-07-22 富山化学工業株式会社 パズフロキサシン細粒剤
JP4299384B2 (ja) * 1997-07-15 2009-07-22 富山化学工業株式会社 溶出遅延防止細粒剤
IN186245B (es) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
ES2204098T3 (es) 1998-09-14 2004-04-16 Ranbaxy Laboratories, Ltd. Sistema de suministro controlado de medicamentos por via oral con control en el tiempo y en el espacio.

Also Published As

Publication number Publication date
BR0113055A (pt) 2003-07-08
NO20030626L (no) 2003-02-07
US20030176452A1 (en) 2003-09-18
TWI278316B (en) 2007-04-11
CN1444480A (zh) 2003-09-24
RU2287328C2 (ru) 2006-11-20
AU2001276748A1 (en) 2002-02-18
MXPA03001206A (es) 2003-06-30
US6861071B2 (en) 2005-03-01
CA2417764C (en) 2009-05-05
JP3573287B2 (ja) 2004-10-06
CA2417764A1 (en) 2002-02-14
KR100878667B1 (ko) 2009-01-13
EP1308160A1 (en) 2003-05-07
KR20030040348A (ko) 2003-05-22
NO20030626D0 (no) 2003-02-07
NO323835B1 (no) 2007-07-09
US20040132756A1 (en) 2004-07-08
WO2002011726A1 (fr) 2002-02-14
EP1308160A4 (en) 2005-01-19
CN1214792C (zh) 2005-08-17

Similar Documents

Publication Publication Date Title
HN1999000081A (es) Jarabe antihistaminico estabilizado
PT996429E (pt) Solucoes e dispersoes no estado solido de farmacosfracamente soluveis em agua
UA94065C2 (en) Dihydropseudoerythromycin derivatives
BRPI0513149A (pt) uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito
HN2002000247A (es) Derivados de sulfonamida
HK1075205A1 (en) Combination of selected opioids with muscarine antagonists for treating urinary incontinence
DE60111500D1 (de) Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
PA8554501A1 (es) Composicion fungicida basada en derivados de arilamidina y compuestos fungicos conocidos
DE60319406D1 (de) Meso-substituierte porphyrine
PT96506A (pt) Processo para a preparacao de composicoes orais que incorporam como ingrediente activo pimobendano
AR027967A1 (es) Derivados de esteres de pirazol como agentes antinflamatorios/analgesicos
EA200200492A1 (ru) Растворы, содержащие эпинастин
BR0312099A (pt) Uso de toxina bolutìnica, bem como composição farmacêutica
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
MXPA03010801A (es) Material polimerico que contiene un acido latente.
AR030128A1 (es) Una preparacion solida altamente absorbible
MXPA05009500A (es) Derivado de benzofurano.
WO2003045326A3 (en) Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
BR0108500A (pt) Arilpiperazinas e arilpiperidinas e seu uso como agentes inibidores de metaloproteinase
NO20055882L (no) Farmasoytiske formuleringer omfattende amoksicillin og klavulanat
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
DE60125672D1 (de) Vom Tetrahydrofurfuryl abstammende, sauerstoffhaltige Verbindungen enthaltende Dieselbrennstoffzusammensetzungen
EA200101001A1 (ru) Декурсинол или его производное в качестве аналгезирующего средства
DE60100704D1 (de) Porphyrine und verwandte verbindungen

Legal Events

Date Code Title Description
FB Suspension of granting procedure